MOPA — Medical Oncology Prior Authorization - Local Development build (v0.1.1-snapshot-080926) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
| Official URL: http://hl7.org/fhir/us/codex-mopa/ImplementationGuide/hl7.fhir.us.codex-mopa | Version: 0.1.1-snapshot-080926 | ||||
| IG Standards status: Draft | Maturity Level: 0 | Computable Name: MOPAIG | |||
This implementation guide defines the Medical Oncology Prior Authorization (MOPA) framework. It is intentionally informative: it documents the oncology PA workflow, the gaps in Da Vinci CRD/DTR/PAS and mCODE, and the upstream proposals needed to close those gaps.
Getting cancer treatment approved takes too long. For patients with breast cancer and other oncology diagnoses, prior authorization is fragmented, slow, and disconnected from the clinical evidence that guided the treatment decision. There is no shared, standards-based language for oncology treatment decisions and no common way to move the right clinical data from the point of care to the authorization system at the right moment.
The regulatory pressure is now direct. CMS-0062-P (April 2026) extends prior authorization requirements to prescription drugs — including chemotherapeutics and anti-cancer agents.
This IG defines a structured authorization exchange using the standard Da Vinci CRD workflow where the payer CRD service uses FHIR authorization (when provided) to query the EHR for required oncology patient context (diagnosis, staging, biomarkers, line of therapy) directly.
The workflow uses two CDS Hooks stages:
order-select (informational) — the CRD service evaluates approvability and returns
advisory cards before the provider signs the orderorder-sign (final determination) — the CRD service returns the binding coverage
determinationFor the upstream standards work items, see:
In scope:
Out of scope (this version):
| Stakeholder | Benefit |
|---|---|
| Oncology Practice / Clinician | Clinical guideline-aligned recommendations surface at the moment of ordering — structuring the treatment decision in a way that moves through authorization without friction |
| Cancer Patient | Clinical guideline-appropriate treatment is authorized faster because the clinical evidence supporting the decision arrives at the payer in a structured, computable form |
| Health Plan / Payer | Authorization requests carry the structured clinical evidence — diagnosis, staging, biomarkers, line of therapy — that coverage policy requires, enabling consistent, evidence-grounded determinations |
| EHR / Ordering System | A single conformant integration delivers clinical guideline-aligned CDS and structured authorization requests across all payers and cancer types, replacing fragmented per-payer builds |
| Clinical Guideline Authority | Computable regimen definitions flow directly from publication into clinical decision support and payer coverage evaluation — creating a traceable path from evidence to real-world treatment authorization |
| Implementation Guide | Version | Role |
|---|---|---|
| US Core | 7.0.0 | Base US patient, practitioner, and clinical data profiles |
| mCODE | 4.0.0 | Oncology clinical data foundation |
| Da Vinci CRD | 2.2.1 | Coverage Requirements Discovery workflow backbone |
| Da Vinci DTR | 2.2.0 | Documentation Templates and Rules |
| Da Vinci PAS | 2.2.1 | Prior Authorization Support |
PlanDefinition and RequestGroupThis publication includes IP covered under the following statements.